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 ABSTRACT 
 
 
 
This paper examines the Pharmaceutical (Pharma) industry and the changes that 
have occurred particularly over the last 10 years as a result of the overall economic 
downturn, the rising cost of healthcare and the costs associated with the development and 
sales of pharmaceuticals. One response of big Pharma to this has been the recent spate of 
partnerships, mergers and acquisitions, consolidation, diversification, licensing 
agreements and downsizing in both human and capital resources. 
Four major challenges facing the complex Pharma industry are highlighted and 
discussed. These  include the decline in the discovery, approval  and marketing of new 
chemical entities (NCE) with fewer and fewer blockbuster drugs making it to the market, 
competition from generics drugs, regulatory pressures and the weak growth in the US 
market (the largest market) and therefore the need to explore other markets to name a few. 
In addition to the research driven aspect of the paper, a summary of the interviews 
conducted with executives and other industry practitioners (to get their personal views) is 
presented. 
Finally referencing some of the strategies adapted by some companies, this thesis 
identifies Organizational Dynamics areas of concentration and the role they can play 
within companies in their plans to ensure long term viability. The analysis focuses on the 
commercial aspects of the industry and offers some steps that will be useful in changing 
the current business model and setting the stage for future success. 
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CHAPTER 1 
 
INTRODUCTION 
 
Background 
The Pharmaceutical industry and big Pharma ( < $3 billion annual sales) in 
particular are now experiencing the same phenomenon that many other industries have 
faced in the past where many companies have been forced to try and reinvent themselves 
in the face of challenges in their business environment. It happened with the computer 
industry for example International Business Machine Corporation (IBM) moving to a 
service model, the steel industry (outsourcing and diversification) and more recently, the 
technology sector with the bursting of the dotcom bubble. One thing has become clear. 
Only the companies that are willing to change or modify their strategies and follow that 
with excellent execution of these strategies will have long term success. 
The issues involved are very complex and cover a wide variety of areas including 
research and development, commercial, political and geographical to name a few. This 
paper explores the commercial or business issues and their impact on the current Pharma 
business model. It will also look at strategies being devised to address the lack of 
innovative new products being developed and approved and the negative impact they 
have on revenue growth. It will also provide some steps and suggestions that will be 
helpful in addressing the issue based on changing the changing environment. It will 
examine the strategies that can be used in focusing research and development as well as 
changing business models that can be used to mitigate the loss in revenue caused by the 
patent expiration and a lack of blockbuster medicines to replace them, both in the 
developed and Emerging Markets. 
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The performance of companies that attempt to change their business models via a 
variety of approaches, primarily mergers and acquisitions (M&A) will also be examined. 
While it is difficult to predict or project how companies will fare after a significant 
change it its operating model or structure,, the early results are very important because 
investors and analysts are very often quick to reward or punish companies based on their 
ability to deliver on their pre-merger or pre reorganization promises.  
A perfect example of this was the difference in early evaluation between the 
Pfizer and Wyeth vs. the Merck and Schering Plough mergers. In the February 17th 2010 
issue of FiercePharma Tracy Stanton wrote: 
Not only have analysts predicted solid growth for the new Merck, but have been 
praising management for its discipline and commitment. While as you know, 
Pfizer execs got an earful of criticism—and a stock price hit—when its forecast 
post merger sales substantially lower that it had predicted earlier. 
A few weeks later on March 2nd, 2010 the same reporter wrote  
Suddenly, Pfizer is the belle of the hedge-fund ball. Reuters reports that "some of 
the savviest" of hedge funds are eyeing the company, now that it has on hand the 
new drugs and vaccines it bought along with Wyeth. Apparently, these 
professional investors believe the rationale around that $68 billion deal: That 
Wyeth's products will make up for Lipitor's fall off the patent cliff. 
Many big Pharma companies have responded to the current business climate by 
engaging in a variety of strategies aimed at paving the way for future success. Examples 
of this are, Merck's recent merger with Schering Plough, a move aimed at consolidation 
based on perceived pipeline synergies, the Pfizer buyout of Wyeth and Roche's 
acquisition of Genentech. Others have pursued the path of diversification as is the case 
with Johnson and Johnson, Novartis or Abbot that have significant business activities 
outside of the traditional pharmaceutical arena engaging in areas such as consumer 
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products, healthcare services, medical devices and medical diagnostics. Yet other 
companies have taken the path of focusing on the 'Emerging Markets' that are in some 
ways considered largely untapped potential like AstraZeneca and GlaxoSmithKline's  
focus on China and India respectively. 
These are examples of changes that point to the fact that many Pharma companies 
do not see the current situation as a temporary setback. Many are making the decision to 
work with former competitors (Eli Lilly, Merck and Pfizer working on Oncology in Asia,) 
or revamp their research capabilities as seen with Eli Lilly and Covance recently signing 
a 3 year biotechnology services agreement  where Lilly will test bioproducts at Covance's 
new biotech facility (Lilly February 26, 2010 press release). Companies are also trying to  
improve their manufacturing capacity and efficiency (many with a variety of Six Sigma 
process improvements)  and commercial models (Merck embarking on a new way of 
engaging with their customers) in order to be successful in the future. 
There is no doubt that the Pharma industry is facing challenging times, and only 
the companies that are able to (1) execute on the strategy they develop as well as (2) 
carefully assess and manage the risks, (3) make the right portfolio and business decisions 
and (4) improve their processes will be able to have long term success.  
Chapter 1 outlines some of the issues being faced by the industry as well as some 
projections on where the solutions may be found. Chapter 2 takes a look a ways in which 
some companies have already responded by trying to find ways to modify the way they 
do business, including looking for ways to buy or partner to get assets they currently do 
not have in their portfolio.Chapter 3 recaps the views expressed by subject matter experts 
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on the industry. These interviewees were selected based on their extensive experience in 
the Pharma industry including research and development, global marketing, mergers and 
acquisitions, portfolio management, consulting, sales and marketing experience.  
Chapter 4 examines past mergers in more detail, looking at examples where 
companies made the decision to merge assets and the resulting performance of the 
combined entity. This is very important because in the future more and more companies 
may chose to go this path and it will be very important to understand how close they 
came to achieving their targeted objectives, both in the short and long term. In chapters 5, 
6 7, 8 and 9 potential approaches and solutions to address the main issues will be 
proposed, incorporating some of the disciplines, processes and tools from the 
Organizational Dynamics program at the University of Pennsylvania while chapter 10 
brings it all together in a summary that reiterates the sense of urgency and steps needed to 
address the issues impacting this very complex and now fast paced industry. 
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PHARMACEUTICAL INDUSTRY ISSUES  
Limited Approval of New Chemical Entities) 
New Chemical Entities (NCEs) are the compounds that emerge from the process 
of drug discovery. Research done by IMS research shows that there has been a significant 
decline in the number of NCEs launched over the last ten years. A plot of the IMS data 
(Figure 1) shows a decline in the NCE launches from 45 in 1999 down to approximately 
27 by the end of 2009. This phenomenon has not been restricted to just a few therapeutic 
areas or companies and is compounded by the fact that the value of the launches that have 
occurred are significantly less than in the years when blockbusters drugs provided 
significant increase in revenue 
Figure 1 - Expected NCE Launches for 1999-2009 
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The reason for this decline has been attributed to many factors including increased 
scrutiny and higher safety standards dictated by the Food and Drug Administration (FDA) 
authorities, broad portfolio of early stage therapeutic products being looked at but with 
not much success in creating novel medicines in the vast majority of the areas, despite 
advances in technology and processes. Regardless of the reasons, the companies have to 
deal with the reality that there are less new products being approved and therefore they 
are failing to achieve their potential to provide treatment for patients and commercial 
benefits to their companies. Figure 2 shows the fate of some promising drugs over the last 
few years. 
Figure 2 - Product Delays and Non-Approvals 
 
While the solution to this problem starts in the area of research and development 
(R&D), the business aspects is of critical importance. It takes about 10–12 years to bring 
a medicine to market from discovery through launch. While it may be possible to 
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decrease this time using better processes and technology, fixing the business model 
where each company invests in R& D from discovery through product launch (lifecycle 
management) is just as critical.  Additionally, companies need to make better portfolio 
decisions that enables them to sharpen the focus of their investments and where possible 
look for opportunities to work with other entities to share the cost of R&D as well as the 
business risks. 
Increased Generic Competition 
Generic drugs have always been a big challenge for the established big Pharma 
companies. Big Pharma companies spend many years and millions of dollars 
(approximately $802 million estimated by the Congressional Budget Office, CBO) from 
discovery to product launch. In 1976 the estimate was $137 million dollars and by 1990 it 
had increased to $445 million dollars. These companies are able to take advantage of 
their hard work and investments while their patents are in effect, but as soon as these 
patents expire, the generic drug makers are able to undercut the big Pharma profit margin 
within 6 months by producing lower cost, and in most cases very effective alternatives 
(See Figures 3 and 4).  
Figure 3 – High Level Breakdown of R&D Cost 
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Figure 4 - Estimates of R&D Costs 
 
 
The recent economic downturn, healthcare reform in many countries and less 
disposable income for customers have made the generic option more attractive to payors, 
insurance companies and consumers concerned with managing their costs. As a result the 
generic drug makers have been making inroads in the product sales of the branded 
products and this along with patent expiration has led to projections of an increase in 
generic sales of $12 billion dollars from $18 billion in 2008 to $30 billion in 2012 (see 
Figure 5).  
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Figure 5 - Generic Sales Projections Through 2012 
 
 
Generic drugs are here to stay, and many will argue that they play a very 
important part in dampening the rising cost of healthcare for consumers, especially with 
the ever increasing medical and insurance costs. In this environment big Pharma 
companies need to get creative and change or modify their business model to be 
successful. Options available to them could include, improving their product lifecycle 
process to provide additional value to patients on compounds that currently exist, 
partnering with biotech and generic companies to discover additional indications and uses 
for their products. Another approach that could be considered is to develop their own 
generic drug infrastructure and competence so they can tap into certain markets where the 
cost of brand drugs may be prohibitive, but the generic versions could help them to gain 
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access to the market or region once the patent life has expired. This would help them to 
develop brand recognition. 
Regulatory Changes and Political Impact 
The recent (2006–2010) economic downturn has in many situations intensified 
and refocused people's attention on regulation in the Pharma industry. Some of the 
arguments in the fall of 2009 healthcare debate in the United States are a prime example. 
The debate has been driven both by the need for the improvement in the regulatory 
process to meet the current needs of all the stakeholders as well as the stated and in some 
cases implied need to ensure that the expected benefits are aligned with the cost for the 
insurance, products and services. 
This reality will prompt and in many cases force big Pharma companies to 
revamp their cost structures as governments, insurance companies, payors and patients 
focus on reducing the spending on healthcare. Figure 6 shows the cost forecast by the 
Congressional Budget Office which will rise to 25% of the US GDP by 2025 if the 
current trend continues. 
These cost and other related issues could be seen more as the symptom of the 
underlying problem. The real issue is that there is a need for Pharma companies to be 
able to demonstrate the value they bring to their patients and other stakeholders. In other 
words, show the value that can be provided to the patient by the products they submit for 
approval, especially where they are in therapeutic areas that are already being addressed 
while the needs of many others are not met or are underserved.  
The Food and Drug Administration (FDA) in the Unites States and other like 
organizations in other countries have as one of their main mandates, the health and safety 
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of the society. Big Pharma could partner with these agencies by leveraging some of the 
cutting edge technology they (big Pharma) have to speed up their processes, a win-win 
proposition (see Figure 6). This would also require a higher level of communication and 
openness than currently exists so the needs and safety of patients are put first in all 
interactions.  
Figure 6 - Healthcare Spending Trends 
 
    
Regulation also impacts many other issues and stakeholders concerned about 
issues like Global Warming (the effects of manufacturing plants on the environment) 
Animal Rights groups (resistance to testing in animals) and many other groups. These 
groups often have not only the monetary resources but also the political connections that 
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can make it very difficult for Pharma companies to operate to their full potential in many 
countries and markets. Pharma companies would  be well served to understand the 
concerns and improve these relationships and not get into a situation where they have 
trouble marketing and selling their products after clearing the high hurdle of research and 
development and passing product efficacy and safety clinical trials. 
The Emerging Markets (Changing Disease Patterns, Patient Demographics) 
The United States is by far the biggest market for Pharmaceuticals. Many 
companies recognize the need to start putting more resources and infrastructure in other 
regions and countries that have the potential to become significant sources of growth in 
the very near future. China and India are the countries that readily come to mind, but 
countries like Brazil, Russia and even Poland are being looked at as markets that still 
have significant areas where the needs of patients with certain diseases are not being met.  
In Figures 7 and 8 the IMS research identifies the following countries as the E7, 
China, India, Brazil, Russia, Turkey, Poland, South Korea while others include Mexico or 
Indonesia in the place of Poland or S. Korea. Regardless of what countries are identified 
as the E7, these are meant to define the non-industrialized countries with significant 
economic, political, developmental and other growth potential that need to be included in 
their business planning to achieve success on a global scale. 
Many regions have diseases which are not fully understood and may have 
different medical needs because differences in genetics, diet, climate or other factors 
which are unique to their environment. It is important that companies recognize that they 
need to invest in clinical trial and other investigative work before they attempt to 
introduce their portfolio of current products to the region. This like the other problems 
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listed requires rigorous assessment and understanding of the ways of doing business, 
culture and a host of other physiological and social factors, especially in places where 
people have practiced one form of medicine for years. In these cases the solution may be 
a combination of current and new approaches and therapies and not simply going in with 
the goal of replacing treatments that have been used for generations. 
Figure 7 - E7 Health Demographics 
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Figure 8 - E7 Therapy Classes 
 
Big Pharma companies have a responsibility to their shareholders, investors, 
employees and patients to operate in a way that will ensure their viability for the long 
term. That is the only way that they will be able to continue to provide and improve the 
medicines that societies depend on them to produce. The data above illustrates the huge 
opportunity that the Pharma industry has for meeting the need of patients in therapeutic 
areas, as well as and by inference the financial gains they can have in geographies that 
have been a focus of their business plans but have huge and diverse unmet needs. 
Companies should plan to diversify their business models to invest in regions 
where there are opportunities to meet the needs of the people as well as broaden their 
operations. This does not simply mean moving operations to countries where relatively 
lower labor cost may make it possible for them to lower their operating costs and take 
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advantage of manufacturing and supply chain logistics. It also requires them to take a real 
look at disease patterns and needs and not merely take their current portfolio of products 
and try to force fit them into these new regions. To put it directly, Emerging Market 
strategy should include the required level of concern for patient needs as well as the 
necessary business benefits to be effective and increase the potential for long term 
success. 
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CHAPTER 2 
PHARMACEUTICAL INDUSTRY RESPONSE 
 
The issues outlined in chapter 1 are not an exhaustive list of the things big Pharma 
has to rectify, but they represent significant areas which need to be addressed. Many 
organizations have been rethinking their business and operational models based on their 
individual situation. Table 1 provides a snapshot of some of the actions taken by some of 
the Pharmaceutical companies in recent years, and from a commercial standpoint shows 
the willingness of Pharma companies to change their way of doing business.  
Table 1 – Actions Taken by Pharmaceutical Companies (2006 – 2009) 
Company Action Reason for Action 
Merck & Co  Acquisition of Schering Plough 
in a reverse merger (11/2009) 
Leverage synergies, 
particularly with the product 
pipeline. 
Pfizer Buyout of Wyeth (10/2009) Solidify #1 ranking and 
increase revenue 
Roche and 
Genentech 
'Partnership' 
Roche acquired Genentech in a 
'friendly' agreement (3/2009) 
Increase focus on innovation; 
Pharma-biotechnology 
innovation 
AstraZeneca Major investments in China (on 
going) 
Invest in infrastructure to 
meet the needs of the local 
customers and patients 
GlaxoSmithKline Major investments in India (on 
going) 
Increase presence in the 
region targeting regional 
unmet medical needs 
Johnson & Johnson Purchased Pfizer's Consumer 
Healthcare department (2006) 
Continued focus on 
diversification 
Norvadis Agreement to acquire an 85% 
stake in the Chinese vaccines 
company (11/2009) 
Strategic initiative to build a 
vaccines industry leader in 
this country and expand the 
Group's limited presence in 
this fast-growing market 
segment. 
Bayer Acquired the portfolio and 
OTC division of privately 
owned Sagmel Inc (2008) 
Increase HealthCare sales 
and market share in the 
Commonwealth of 
Independent States 
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While there have been mergers in the past, the pace and frequency of these 
activities have increased over the past few years (see Chapter 5) as companies identify 
and try to create synergies for their R&D capabilities, improve their pipeline, and 
manufacturing efficiency and  improve their marketing and sales processes. In some ways 
the actions listed above indicate a break from the past where partnerships, mergers and 
other forms of sharing rarely occurred and many tried to grow mostly from within. 
The reality of the need for innovative products, services and new therapies are 
influencing and dictating the need for these changes.  Companies are realizing that if they 
keep doing things the way they have always done them, they most likely will continue to 
get the same results, which have been on a downwards spiral of late, relative to the 1980s 
and 1990s.  
The April 16, 2008 edition of Piribo, the online destination for business 
intelligence for the biotech and Pharmaceutical industry made the following points:  
 
•   The Pharmaceutical markets in India, China and Turkey are expected to grow 
the fastest among all the E7 nations.  
•   The E7 nations are expected to account for nearly half of the 6.99 Billion 
global populations in 2012.  
•   Cardiovascular, cancer and other chronic diseases have taken over 
communicable diseases as the biggest killers in these nations.  
•   The Pharmaceutical market in most of these regions is still dominated by acute 
therapies, but with the growth rate of chronic therapies far exceeding that of acute 
therapies, the therapy mix of the market will be much different in the next five 
years from what it is today. 
 
Many companies have made the first step of recognizing that there is a need to 
change. The problem however comes with ensuring that the proper due diligence is done 
and the right decisions are made based on their specific situation. Changing bad practices 
and adapting the behaviors necessary for success is also a very big challenge. The 
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industry is very complex and as can be seen in Table 1. Many companies are starting to 
make changes that they think will work better to prepare them for the future. The 
headlines referenced below shows that a healthy debate is on going regarding what is the 
best approach for the long term viability of the industry. 
Andrew Jack, a multiple award winning journalist has been writing for the 
Financial Times since 1990, specializing in health and pharmaceuticals since 2004. In the 
March 12, 2009 edition of the Financial Times article titled, "Pharmas try different routes 
to survive' Andrew Jack wrote, "Rarely in the field of pharmaceuticals have so many 
companies adopted such varied strategies in order to survive the intensifying structural 
pressures in their industry"  
He then goes on to describe what he sees as the as the three main approaches 
namely; 
1: Acquisitions like the Pfizer and Merck examples above  
2: Specialization by companies like Shire and AstraZeneca that previously    concentrated 
on 'small molecules' with limited benefits and  
3: Geographical Diversification as mentioned above by GlaxoSmithKline and 
AstraZeneca. 
 In the January 31, 2010 edition Jack wrote. "Large pharmaceutical groups should 
abandon their own early stage drug development and switch to less costly licensing from 
biotech companies, according to a new analysis".  
The views expressed below in the June 2, 2009 edition of Jack's article in the 
Financial Times is another good example of the disparate views and opinions on how the 
issues can be resolved: 
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I have not seen value creation through pharmaceutical mergers in the past 10 
years," says Steve Arlington, head of the pharma R&D practice at PwC, the 
professional services firm. "The industry has suffered from disruption through 
mergers, post-merger activity. Can big pharma become too big? You see a loss of 
leadership. The internal machine becomes very complex, and compliance 
overtakes leadership." But Daniel Vasella, chairman and chief executive of 
Novartis, who had an active role in the Swiss company's creation through the 
merger of Ciba-Geigy and Sandoz in 1996, as well as several big takeovers since, 
is more positive. He argues that some companies might have been in a far worse 
shape if they had not combined. "An industry which has mounting pressure has a 
tendency to consolidate," he says. "It's a normal process. We have not yet reached 
the point of lethal size which is destructive. 
In the February 12, 2010 article of Business Week, Fred Hassan, the former CEO 
of Schering Plough before the merger with Merck is quoted as saying: 
"Large drugmakers will need to merge in order to fund expensive, complex areas 
of research, such as Alzheimer’s disease, Hassan said today in an interview on 
Bloomberg TV. Smaller companies also will be forced to sell themselves as they 
run out of cash in the tight credit markets, he said. “One reason deals are 
necessary is because the innovation investments are becoming larger and larger 
and it makes it easier when people can combine their resources to make the big, 
deep bets that you need to make for difficult diseases,” Hassan said. “That is why 
you are going to see more of these deals.” 
These are just a small sample of the views, opinions and recommendations that 
can be found daily in online, television shows Pharma industry trade magazines, books 
and articles submitted by well known and knowledgeable 'experts'. From the research two 
things are very clear, one, the issues are very real and companies need to act and two, 
there is not one magic solution that is guaranteed to work. 
The January 11, 2010 edition of the Fierce Pharma newsletter carried the 
following statement:  
"Think the Pharma mega merger is done ... over ... finito? Think again. Some 
analysts and money men are saying that the drug industry is still ripe for 
consolidation. After all, no one company has more than 8 percent of the global 
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market for prescription drugs. And given that market shares are in the single 
digits, says noted venture capitalist G. Steven Burrill of Burrill & Co., "That 
would generally indicate that we have a ways to go on consolidation." Yep, says 
Simon King, a senior analyst at Datamonitor. He told Chemical & Engineering 
News, "There's definitely a couple of large M&A events left in Big Pharma."  
These and other such views and opinions make it apparent that regardless of what 
has happened in the past or is currently happening with mergers, diversification and other 
changes, the need to be able to strategize and execute on these plans is paramount for 
long term success. 
The question then becomes, 'what can the industry do to attain a high degree of 
success in implementing the various commercial strategies being attempted'? The 
potential answers are many, broad in scope and range from the philosophical to the very 
scientific and technical approaches.  It involves moving cautiously and deliberately and at 
the same time making decisions quickly to capitalize on opportunities when they present 
themselves. 
At the organizational level, companies also need to revisit the way they interact 
with government agencies, insurance companies, physicians and patients who as their 
main stakeholders collectively dictate their long term profitability, viability and existence. 
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CHAPTER 3 
INTERVIEW SUMMARY 
While it was important to do extensive industry research to better understand the 
challenges being faced as well as the response by both individual companies and the 
industry, additional work was done to gather information by interviewing professionals 
with extensive Pharma industry experience as well as marketing and academic expertise. 
The sample size was limited, 6 interviewees (see appendix A), representing over 140 
years of collective experience with knowledge and expertise in Marketing, Sales, 
Research and Development, Consulting, Academia and Business Development at 
executive level.  
The responses to the questions (Appendix B) showed that there was agreement 
with the view that the current business model was not working. While there was 
acknowledgement that it all starts with the pipeline, the collective responses indicated 
that there were many other factors that contributed to the problems being faced by big 
Pharma. These factors include, ineffective product lifecycle management, ineffective 
selling models resulting in limited access and usage, ineffective articulation of the 
Pharma value proposition and lack of creativity and innovation in providing the 
medicines and services to meet the growing and diverse unmet medical needs of society. 
The table below summarizes the responses with the number of similar answers 
indicated in the parentheses. The responses are not verbatim but represent the main points 
expressed using the 'affinity diagram' process approach. 
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Table 2 – Results of Interview on the Pharma Industry 
 
Changes in 
Pharma over the 
last 5-10 years 
Commercial 
Issues/Experience 
Companies Need 
to Address 
Commercially 
Commercial 
Imperatives 
Less blockbuster 
drugs being 
approved (6) 
Limited access to 
doctors via sales reps 
(4) 
Lack of diversity 
in the pipeline/ 
therapeutic areas 
targeted (5) 
Develop global 
strategies specific to 
targeted regions e.g. 
Emerging Markets 
(4)  
Healthcare 
reimbursement 
and issues have 
become more 
visible (4) 
More regulatory 
focus driven, much 
driven by politics 
and safety concerns 
(4) 
Perception that 
they are not 
focused on the 
patients (2) 
Assess and address 
unmet needs (4) 
More market share 
being captured by 
generic drugs (3) 
Shrinking pipeline 
resulting in reduced 
number of products to 
market (3) 
Ineffective, 
inflexible selling 
model (3) 
Develop new/better 
go to market models 
(3) 
More 
consolidation; e.g. 
(Mergers and 
Acquisitions) M&A  
(5) 
Increased 
'consumerism'  
- more demands 
- price pressure (3) 
Lack of creativity 
and innovation (3) 
Effectively 
implement business 
and culture 
changes after M & 
A (4) 
Flat to declining 
sales (2) 
Commercial model is 
'dead' 
- ineffective 
- value not articulated 
(2) 
Perception of 
arrogance by 
many stakeholders 
- doctors, patients, 
policy makers (3) 
Communicate more 
clearly and openly 
with customers (2) 
Higher presence of 
biotech companies 
(2) 
Too much focus on 
blockbuster drugs for 
commercial success 
(3) 
Effectively 
communicate 
value proposition 
(3) 
Make M&A and 
partnerships 
strategic and 
focused (5) 
 
Note: Conducted to gain additional Pharma industry perspectives. Sample size= 6 
interviews; parenthetic numbers indicate frequency of mentions 
 
While it would not be prudent to draw any absolute conclusions from such a 
limited group of participants, it is clear from the interview participants agree with most of 
the literature in the various books, newspapers, magazines and online publications 
referenced. It would be very hard to find an informed Pharma professionals or industry 
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analysts who would disagree with the findings above based on all that is has happened 
over the past few years.. The news, articles and even Wall Street discuss these 
happenings almost daily and of course, there is no shortage of proposed solutions on 
ways to fix the issues. 
What may be more difficult is to find people who will agree on any single 
approach to rectify the problem. It was interesting to note that most of the respondents 
saw the competition from generic drug companies as a drain on the big Pharma revenue 
base, but no one suggested focusing the efforts at taking back market share from the 
generic companies once the patents have expired as a strategy. Instead, the views 
expressed suggested that big Pharma is in control of its destiny, and the focus should be 
on things like, creating innovative medicines, diversifying the product and service 
portfolio and fixing the ineffective business and selling models. 
With the Pharma industry being very complex, from the research and 
development of a molecule to the administering of the prescribed drug, there was no 
consensus on the best way to fix the commercial issues listed in the research or the 
interviews. Each organization will need to assess its situation based on all the factors 
such as history, culture, areas of competence, business models etc, which are too many to 
be covered in this capstone thesis.  
The approach proposed in the next few chapters should provide some valuable 
insights into how organizations can take the initial steps to incorporate some valuable 
tools and processes to address the very daunting task facing each and every organization 
in the industry. Chapter 4 will provide some details on how mergers and acquisitions 
have been approached and performed in recent years. 
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CHAPTER 4 
OVERVIEW – PAST MERGERS AND ACQUISITIONS 
Most organizations look to mergers and acquisitions (M&A) and other such 
partnerships as the one of their first option to addressing the problems they face. The big 
Pharma companies look to the smaller companies and biotech to provide competences or 
additional resources to help spur R&D as well as Marketing and Sales (M&S) growth, 
and the smaller companies in turn get much needed funding to continue their work, either 
as partners or as a part of the larger company. 
In a study, Big Pharma Mega Mergers 1995 – 2014 published in December 2009,  
 
Datamonitor classified four M&A growth strategies (see Table 3).  
 
 
Table 3 - Grouping of Big Pharma Companies by M&A Growth Strategy (adapted from 
Datamoniter) 
 
Four Classes of M& A Strategy 
Buy Growth 
Companies 
Buy Scale 
Companies 
Multi M&A 
Companies 
Organic Companies 
Roche-Genentech 
Johnson & Johnson 
Abbott-Solvay 
Merck-Schering-
Plough 
GlaxoSmithKline 
Sanofi Aventis 
AstraZeneca 
Bayer AG 
Pfizer-Wyeth 
Novartis 
Eli Lilly 
Bristol-Myers Squibb 
 
1. Buy Growth Companies– activity primarily aimed at increasing the growth of 
prescription sales 
2. Buy Scale Companies – activity to increase product pipeline, R&D, M&S etc. 
3. Multi M&A Companies – employ two or more of the strategies 
4. Organic Growth Companies – avoid M&A as a core strategy 
The goal is to take a look at examples of M&As that have occurred and to provide some  
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perspectives on how each combined company performed. It is not meant to be an in- 
 
depth study of the various kinds of M&As (see Table 4, (adapted from Big Pharma Mega 
 
 Mergers 1995–2014, Page 13) 
 
Table 4 – M&A Overview 1995-2014  
 
Year Acquirer Target Value($bn) Combined Rx 
Sales ($bn) 
1996 Ciba-Geigy Sandoz 36.0bn 14.4bn 
1997 Roche Boehringer 
Mannheim 
11.0bn 11.9bn 
Astra Zeneca 37.7bn 14.8bn 
Sanofi Synthelabo n/a 7.9bn 
1999 
Johnson & 
Johnson 
Centocor 4.9bn 12.0bn 
Pfizer Warner-
Lambert 
90.0bn 22.6bn 
Glaxo 
Wellcome 
SmithKline 
Beecham 
85.3bn 28.6bn 
2000 
Abbott Knoll 6.9bn 6.5bn 
Johnson & 
Johnson 
Alza 12.3bn 14.9bn 2001 
Bristol-Myers 
Squibb 
Dupont 7.8bn 12.9bn 
2003 Pfizer Pharmacia 60.0bn 46.1bn 
2004 Sanofi Aventis 82.0bn 38.2bn 
2005 Novartis Hexal 8.3bn 25.0bn 
Novartis Chiron 5.1bn 29.5bn 2006 
Bayer Schering 24.9bn  
2007 AstraZeneca MedIumme 15.6bn 30.7bn 
2008 Eli Lilly ImClone 6.5bn 18.8bn 
Roche Genentech 46.9bn 36.1bn 
Pfizer Wyeth 68bn 60.0bn 
Merck & Co. Schering-
Plough 
41.1bn 41.9bn 
2009 
Abbott Solvay 6.6bn 19.8bn 
2010 Novartis Alcon TBC 43.0bn 
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Snapshot of M&A Results 
The performance of the combined companies was assessed using a variety of 
financial measures such as: 
 Profit margin (Earnings Before Interest and Taxes/total revenues) 
 Capital turnover (total revenues/capital employed) 
 Return on capital employed (EBIT/capital employed) 
 Market capitalization 
Of the 22 transactions large scale (large scale = valued above $5 billion) M&A 
activity studied Datamonitor found that only 3 delivered fast growth performance over 
the next 5 year period. The study results had the following observations, "Only three 
M&A events have delivered fast growth performance over subsequent five year period" 
 Only the small-sized acquisitions have delivered a subsequent fast sales growth 
performance over the next five years (Centocor, Knoll and Genentech) 
 No big or medium sized acquisitions have contributed to fast sales growth 
performance in the next five-year period. 
 Nearly all big and medium sized acquisitions have delivered a flat sales growth 
performance in the five year period after the merger 
 Only 2 large scale acquisitions have provided medium sales growth performance 
in the 5 years after the merger (Warner-Lambert, acquired by Pfizer and Zeneca, 
acquired by Astra). 
While only 3 of the large M&A organizations gained the targeted fast growth 
performance pace in the first 5 years, it is important to note that the small or flat growth 
in many ways stabilized their balance sheet in an environment where many of them are 
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facing patent expiry over the next few years as the so called 'patent cliff' looms. This is 
seen as relative success to many because without this small growth many companies 
would have had a steep decline in growth as their branded products lost patent protection. 
Generally speaking, however, big Pharma companies seem to be playing "follow 
the leader" too much, says Wharton management professor Saikat Chaudhuri 
whose work focuses on mergers and acquisitions. "They don't do a good job of 
portfolio management. They tend to all go after the same things. They tend to be 
conservative and place their [M&A] bets on [a narrow range] of drugs." 
Knowledge@ Wharton February 3, 2010). 
 
The current (spring 2010) healthcare situations will continue to impact the 
companies as the after effects of the recent recession continue to reverberate around the 
world. This is truly a global economy and the business environment continues to evolve 
even as companies continue to implement new approaches to improve their product 
pipeline and look for new patients and markets to serve.  While doing this they need to do 
rigorous business assessments to ensure that their strategies are financially sound, 
informed by strong portfolio management to target areas where they can provide novel 
medicines in therapeutic areas not addressed, establish rigorous process improvement to 
ensure that they maintain and improve their operations to gain efficiency and minimize 
safety issues and institute comprehensive risk management in almost everything they do.  
Additionally, the one area that should not be underestimated is the effort it will 
require to integrate companies after a merger. They will also need to setup organizations 
to make the partnerships successful and do the due diligence to ensure that they are able 
to operate and conduct business in countries where business and cultural norms are far 
different their current experiences. 
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CHAPTER 5 
LIMITED APPROVAL OF NEW PRODUCTS (NCE) 
To address the limited approval of new products companies need to continue to 
look for ways to discover and develop new medicines in different therapeutic classes 
while effectively managing and optimizing the product life cycle for current products. 
This requires investments not just in R&D but also in market research and other areas to 
ensure that the molecules entering the pipeline are included in their strategic plans. It also 
means the decisions need to be made to take advantage of the value of molecules in the 
pipeline that do not align with the strategy, but may be of value to other organizations. 
This may involve exploring different kind engagement with smaller Pharma companies, 
generic drug makers, biotech companies as well as competitors who may be better able to 
take advantage of the value already created in the early stage R&D and integrate them in 
their pipeline based on their strategies. 
Portfolio Management 
One discipline taught in Organizational Dynamics that would be useful in helping 
companies do a proper assessment of their business model is Portfolio Management. For 
the purposes of this paper portfolio management will be defined as "the active 
management of a collection of assets whose consolidated purpose is to aid in the 
attainment of one or more organizational/enterprise goals under constrained resource 
conditions" (Bayney 2007).  
With limited resources being available to them, companies need to prioritize their 
portfolio of products and where they have areas that align with their strategy, optimize 
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the molecules in the pipeline and maximize the overall value contained in the portfolio 
(see Figure 9).  
Figure 9 – Portfolio Management Objectives (adapted from Bayney 2007) 
 
 
 
For Pharma companies a big part of this process will include looking at areas 
where there are opportunities to address un-met needs. An example of the kind of change 
needed in the industry going forward was the announcement on February 23, 2010 of the 
formation of the Asian Cancer Research Group Inc., (ACRG) by three major Pharma 
companies, Eli Lilly, Merck & Co. and Pfizer. The objective of this independent not-for-
profit entity is to speed up the early stage R&D and therefore the treatment for patients 
affected with the most commonly diagnosed cancers in Asia. 
If the ACRG lives up to it potential, (and that will be very challenging by virtue 
of having to overcome all the issues of change management, culture and integration just 
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to name a few things) there is a possibility that it can have a positive impact on all the 
issues listed in chapter 1. This represents work in just one disease area (oncology), but 
has the potential to significantly decrease the amount of spending if each company did it 
alone ($335 million in the pre-clinical phase) as well as increase the potential for early 
successes because of the collaboration and sharing of expertise and experience. It can 
also help with the Emerging Market Strategy because the types of cancers found in Asia 
may be different than those currently being addressed in the US and Europe because of 
demographic, hereditary, genetic, environmental and other factors. Finally it could serve 
as a useful model for future collaborations across the industry if it is successful along 
with some of the steps outlined in Table 5. 
Table 5 - Key Steps to Address Limited Approval of New 
 
Action Intent 
1. Develop strategy and determine 
therapeutic areas of focus 
Sharpen focus and make strategic and 
communicate long term business goals 
2. Assess current pipeline or molecules and 
medicines and determine where they align 
with the strategy 
Make informed portfolio decision based on 
strategy, resources available and sound 
business cases 
3. Establish a process to augment portfolio 
elements that align with the strategic 
therapeutic areas by forming partnerships 
or establishing business relationships with 
entities conducting preclinical studies 
Minimize upfront costs and mitigate R&D 
risks by investing in late stage development 
from other organizations. 
4. Divest valuable pipeline elements that do 
not align with the strategic therapeutic 
areas of focus 
Maximize benefits from R&D efforts 
already expended. 
5. Update and improve where possible all 
processes in the product life cycle from 
basic R&D through product approval 
Look for opportunities to optimize the 
portfolio by increasing the speed of R&D, 
improve safety and reduce operational 
costs 
6. Invest time and effort to understand and 
plan for the organizational and cultural 
dynamics that can lead to failure even if the 
science and technology works as planned 
Avoid the mistake many companies have 
made in not understanding and addressing 
these critical areas 
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CHAPTER 6 
 
INCREASED GENERIC COMPETITION 
The February 25, 2010 report by Bloomberg has an article in which Eli Lilly's 
CEO John Lechleiter is quoted as saying "increasing the efficiency and speed of 
developing innovative products is the company's key to offset an anticipated $10-billion 
loss in annual sales due to generic competition by the end of 2016". The executive 
remarked that his and the company's response "has to be, 'Where do we find and how do 
we bring forth new innovation as quickly and cost-effectively as possible?' That’s what 
we're working on."  Many companies in the industry are modifying their strategies in 
response to the challenges they face and as is the case with most things, planning and 
executing these strategies effectively will be critical. 
Generic drugs are here to stay, and many people believe that they play a critical 
role in making patient care more affordable and are just as effective. From a commercial 
standpoint there may be many ways that big Pharma companies can benefit from 
establishing different levels of partnerships with generic companies or even establishing 
their own generic drug businesses, especially in countries where their branded products 
may not have a presence. This is not to suggest going away from the model of trying to 
develop blockbuster drugs, especially in areas where there are untreated diseases. It is 
suggesting that diversifying their business models in a way that addresses therapeutic 
areas that have not been addressed with the added benefit of spreading their business 
opportunities and risks.  
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To do this will require developing a different mindset with regards to how they 
operate with the current and future environment. This may include embracing the role 
that generic drugs can plan in the Pharma ecosystem and taking advantage of the 
opportunities this presents as seen below in Table 6. 
Table 6 - Key Steps to Address Increased Generic Competition 
 
Action Intent 
1. Assess the current product portfolio and 
determine how to maximize the value by 
looking at new markets, seeking additional 
indications that can benefit patients and the 
company's bottom line 
Focus on lifecycle management and 
develop standard processes and tools to 
make this a part of the organization 
functions under normal operating 
conditions. 
2. Revisit the business model and look for 
opportunities to partner with existing 
generic drug makers to ensure that patient 
safety is impacted because of differences 
between the brand and generic drug 
Maintain patient safety and develop and 
maintain brand loyalty 
3. Assess business model and look for 
areas where establishing a generic business 
through M&A or organic growth maybe 
beneficial. This could be especially 
important in developing countries where 
there is currently little or no availability 
and accessibility of cutting edge medicines 
Address un-met medical needs, enlarge the 
global business footprint and diversify 
sources of revenue 
4. Invest more in biologic therapies Broaden potential sources of treatments for 
patient care 
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CHAPTER 7 
REGULATORY CHANGES AND THE ASSOCIATED POLITICAL IMPACT 
All the factors outlined in chapter 1 are very important, but the issue of regulatory 
changes and the associated political fallout has one of the biggest impacts on big Pharma 
companies because this is the final hurdle companies have to overcome to get their 
medicines to patients after investing hundreds of millions of dollars.  
In the recent years many companies have embarked on a process to implement 
what has been called 'New Commercial Models', which is basically changing the way 
they interact with all their stakeholders and customers including governments and 
regulatory agencies, doctors, patients and other caregivers. While a big aspect of this is 
focused on the marketing and sales of products, there is also a component that tries to 
show improved openness and sharing with agencies, especially in the areas of 
transparency on product efficacy and safety. This is not only practical, but it also has a 
political aspect in trying to show good faith and a sense of partnership with the agencies. 
There is also more emphasis on stemming the flow of 'me too' products being 
approved to encourage or even force Pharma companies to be more innovative and invest 
in therapeutic and disease areas where medicines and healthcare solutions are lacking. 
This is an area where companies could really begin to add value to agencies like the FDA 
by provide technological help in looking for ways to assess safety and efficacy concerns 
in addition to being more open and therefore develop a more trusting working 
relationship. 
Big Pharma companies have for a long time been characterized as big spending, 
greedy and solely motivated by profit, especially when there are discussions about the 
34 
price of prescription medicines. This has led to some restrictions being put on many 
marketing and sales activities, especially where it pertains to sales representatives giving 
gifts and other valuables to physicians and other prescribe the medicines. Some 
companies have even made the extra step of disclosing the amount of money given to 
subject matter experts and other people they engage to promote, sponsor or discuss their 
products. 
 In the current and most likely future environment, these companies will have to 
improve and help shape the way they are perceived, and bring to the front the good work 
they are doing not just in producing pharmaceuticals, but also in other areas that benefit 
society and the environment. 
Big Pharma companies have for years been involved in philanthropic and other 
human causes that benefit the wider society. Examples of this include Merck's efforts to 
help cure River Blindness in some parts of Africa, Latin America and the Middle East, 
and GlaxoSmithKline's efforts to eliminate Lymphatic Filariasis in tropical countries. 
These and other like contributions should not directly influence regulation, but in a world 
where perception is reality, the political benefit and goodwill from society can be 
immeasurable. Table 7 describes some of the key steps that need to be taken to start to 
reverse the negative perceptions. 
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Table 7 –Key Steps to Address Regulatory Changes and the Associated Political Impact 
 
Action Intent 
1. Streamline portfolio and focus efforts on 
new and novel medicines that will meet the 
needs not currently being addressed by 
existing treatments, e.g. Alzheimer's 
disease 
Make targeted investments in areas that 
helps advance the treatment of diseases not 
currently being addressed. This also 
demonstrates the behaviors that regulatory 
agencies, healthcare providers and patients 
want to see 
2. Develop a process or standard to clearly 
and transparently communicate product 
safety risks and efficacy to regulatory 
agencies 
Re-establish a working relationship with 
these stakeholders built on trust and 
openness 
3. Continue to seek ways to demonstrate 
the value of the medicines to healthcare 
professionals, other caregivers and patients 
Re-establish the value add and trust with 
these stakeholders who have significant 
political and advocacy standing 
4: Partner with the FDA and regulatory 
agencies to use technology to make the 
approval process more efficient leading to 
quicker approval as well as earlier 
discovery of risk and safety issues  
Make the process better by identifying pass 
or fail indications so the 'wait' period for 
valuable resources can be decreased 
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CHAPTER 8 
THE EMERGING MARKETS (CHANGING DISEASE PATTERNS, 
PATIENTS DEMOGRAPHICS) 
Of the four issues focused on in this paper, taking on the opportunities and threats 
associated with doing business in the Emerging Markets and addressing issues such as 
changing disease patterns and patient demographics may be the issue with the most 
uncertainties and intricacies, even when considering the odds of a molecule becoming a 
successful medicine. While the Emerging Markets present vast and untapped areas for 
Pharmaceutical companies to explore, there is also the uncertainty and potential risk that 
need to be considered when contemplating the level of investment that would be required 
to develop and establish a long term and sustainable business.  
With the slow growth in revenue in the US compounded by the recent global 
economic downturn, Pharma companies have been making attempts to establish a 
presence in the so called Emerging Markets (E7 in Chapter 1). They are making this 
decision because they currently do most of their business in the US and other developed 
countries, primarily in Europe. In many ways this represents the new frontier for these 
companies. This needs to be approached in the same way that a company would approach 
any new venture, with caution and the right amount of due diligence to maximize the 
potential opportunities and minimize the threats.  One strategy would be to use the 
approach of a SWOT analysis.  A few examples of the opportunities presented are: 
1. Rapidly growing economies and populations 
2. Opportunities to learn more about Eastern Medicines and to see where they can 
inform or augment Western Medicine to meet patient need 
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3. Expansion of healthcare infrastructure, systems and to deliver access to drugs. 
4. More people with disposable income to spend on medicine. 
5. Changing medicinal preferences from low cost generic to branded medicine when 
economies of scale can be realized (new concept) 
The threats associated with including the Emerging Markets as a strategy for 
revenue growth include: 
1. Limited knowledge of the markets and culture. This could lead to companies 
creating serious cultural and business transgressions leading to unfavorable 
perceptions of their brands. 
2. Political instability in some regions that could put huge investments in jeopardy 
when there is a change in regime. 
3. Difference in laws and the ways they are interpreted and implemented. 
4. Too much dependence on the countries in the Emerging Markets leading to a lack 
of focus on the developed markets which still provide the majority of the revenue 
and stability. 
5. Lack of acceptance of the medicines by a broad section of the targeted 
populations resulting in unrealized growth. 
This is not just about the research and development. It is also about understanding 
the medicinal needs of the people, the culture, way of doing business and developing a 
partnership with these region and seeing and treating them as equals, and not just as 
revenue potential. 
 If this is done right, Big Pharma companies will benefit greatly not just in terms 
of financial profits, but just as important they could potential reshape some of the 
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negative perceptions by addressing the medicinal needs in areas where the current 
treatment is not enough. Table 8 details some key steps to follow to embark on the 
journey of winning in the Emerging Markets. 
Table 8 - Opportunities in the Emerging Markets (Changing Disease Patterns, Patients 
Demographics) 
 
Action Intent 
1. Take the time to assess the medicinal 
needs of the people in the regions and 
countries they want to do business in. Do 
not just try to introduce products to other 
people just to find a source of additional 
income 
Develop the business based on the needs of 
the people in the Emerging market as well 
as the business need of the Pharma 
company 
2. Make strategic choices in regions, 
countries to invest in based on thorough 
research and analysis of the opportunities 
and threats. 
Doing the due diligence to ensure that there 
is a fit for the individual companies 
3. Partner with regulatory authorities in the 
targeted countries in the Emerging Markets 
(China, India, Brazil etc) to establish 
guidelines for safety and efficacy targets. 
Engage with this key stakeholder in the 
regions to create world class standards that 
will create a solid base for future work built 
on the best technology and knowledge 
developed over decades. 
4. Invest in existing companies (small 
Pharma, generics biotech) to learn about 
the business environment, build R&D, 
manufacturing, supply chain, marketing 
and sales infrastructure 
Demonstrate long term commitment, 
establish relationships and build trust 
5. Develop an organization staffed and 
trained to support the execution of the 
strategy. In addition to scientific and 
business areas this would include investing 
or acquiring competence in areas like 
Change Management, Integration 
Management and other necessary skill-sets 
necessary to deal with the dynamics of a 
growing and changing organization 
Ensure in addition to the normal functional 
areas, the need for the 'softer skills' are 
understood and acquired or developed 
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CHAPTER 9 
LONG TERM AND SHORT TERM RECOMMENDATIONS  
In the 1980s and 1990s, Pharma companies enjoyed very profitable years because 
of the many breakthroughs in medicines, high product margins and for many years, a 
favorable and growing global economy. That is no longer the case, and to succeed now 
and in the future they have to look for new ways and areas of growth as well as look at 
their operating costs and make efforts to bring them in line with their new reality. The 
quick and obvious choice that many companies make is to do things like reducing R&D, 
sales headcount, marketing and promotional spending, consolidate manufacturing 
infrastructure and look for M&A opportunities as discussed in previous chapters.  
The reduction in headcount can bring limited savings but that is not by itself a 
long term solution that supports a growth strategy. Many of the suggestions made in the 
previous chapters can be successful, but they will take time because the Pharm industry is 
a very complex one. Reprioritizing the pipeline and determining the portfolio of 
therapeutic areas on which focus on will take time. Setting up different business models 
to capitalize on the benefits of generic partnership and getting into that business will take 
time. Changing the perception and realizing the benefits of working more in partnership 
with regulatory agencies and other stakeholders will take time, and getting to understand 
and engage in business in the Emerging Markets is also long term proposition.  
Looking at the current operations and finding ways to be more efficient, eliminate 
redundancies, limit health and safety risks in all areas from R&D through sales and 
marketing has the potential to save companies millions of dollars. The rest of this chapter 
will take a look at ways in which process improvement, tied to business outcomes, can 
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help to put companies in a better footing for their business. This is not just doing random 
acts or process improvement or coming up with process improvements that do not 
translate to the bottom line. It is taking a look at all aspects of the operations and seeing 
where improvements can be made in addition to planning to address the problems 
identified.  
Short Term Fixes based on Quality/Quality Improvement 
Genzyme shares fell 22 percent in the last 12 months as the company struggled 
with drug shortages stemming from a virus contamination at its main 
manufacturing plant in Boston (Bloomberg February 22, 2010).   
Eli Lilly has received an FDA warning letter for quality issues in the 
manufacturing of Humalog at its Carolina, Puerto Rico facility. Based upon 
inspections last year, FDA cited the facility for faulty API test methods 
(PharmaManufacturing.com February 25, 2010)  
The headlines above are just a few areas where Pharma companies are 
hemorrhaging significant amount of money and development potential. The loss is not 
just in terms of the actual dollars lost or the resources tied up, but it also includes the 
opportunity cost for the areas where these could have been invested. Process 
improvement is a tool, and like any tool its effectiveness and potential is best realized if it 
is applied correctly, and aimed at helping the organization's operations and ultimately the 
bottom line. 
The Pharma industry could also learn from other industries. The history of the 
consumer electronics industry is well known, with the rise and subsequent decline of 
companies like RCA and others that initially had leading research and development 
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capabilities but at some point lost out to competition because of their inability to respond 
to the changing market environment.  
There are many reasons that could be cited for the shift in leadership in the 
consumer electronics and computer hardware development from US companies to 
companies in Asia, particularly Japan, and at the top of the list would be the quality 
improvement or process improvement movement in addition to the lower cost of labor. 
Process and quality improvement had many leaders like Dr. W. Homer Sarasohn and Dr. 
W. Edwards Demming who were some of the main contributors to teaching the Japanese 
executives and workers quality management.  
The turnaround attributed to post war Japan is well documented, but for the 
purposes of the issues being faced by the Pharma industry today what is important to note 
is that by changing out dated and inefficient ways of doing business, the Japanese 
electronic industry went from being insignificant to the United States industry post World 
War II to being world leaders by the 1990s.  
The same parallel is true for the Japanese automobile industry where quality was 
their biggest selling point until the recent (2009 & 2010) escalation of the issues with 
Toyota cars. Not surprisingly, part of the explanation given for the recent issues was the 
extensive focus on revenue growth at the expense of quality. Only time will tell what the 
long term impact will be on Toyota, but it is safe to assume that this will cause them 
losses in the hundreds of millions if not billions of dollars in addition to placing the onus 
on them to rebuild their reputation for safe and reliable cars, which they had developed 
over a period of decades. The Pharma industry will hopefully learn from the mistakes 
made by Toyota as the try to reinvent themselves and their way of doing business.  
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Long Term Approach Based on an Understanding of the Issues Identified 
It is very important that the current quality issues be addressed to help with 
reducing operational cost for the short and near term. Just as important is the need for 
Pharma companies to look ahead and to not make the mistake of focusing on revenue 
growth and expansion at the expense of quality. To do so would be short sighted and 
have the potential damaging their brand for a very long time. Below are some steps that 
can be taken to create a balance between the need to address the issues identified and 
maintaining and improving quality (see Table 9).  
 
Table 9 - Process Steps to Address the Issues Faced by the Pharma Industry 
 
Process Steps 
 
1: Develop an understanding of  the organization's high level strategy and therapeutic 
areas of focus 
2: Develop a map of the Pharma industry value stream across the product life cycle 
(R&D through to Sales) 
3: Develop a preliminary business case for decisions that have to be made regarding 
M&A and other partnerships and assess the cost of integration 
4: Create a SIPOC for each area (e.g. R&D, Marketing etc) to see where there may be 
gaps or lack of alignment based on the organization's competence or capabilities 
5: Make buy, build, acquire or partner decisions based on the need identified above as 
well as the organization's strategy and integration capabilities 
6: Update the business case and financials and create an implementation and 
integration office to execute the strategy. 
 
 
Each step is explained in the section that follows. 
1: Develop an understanding of the organization's high level strategy and 
therapeutic areas of focus 
This could help with addressing the objectives listed in the Commercial 
Imperatives column in the interview summary (Table 2), particularly where there is a 
need to decide on and focus on the long term strategy. This has to be done at the highest 
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levels of the organization and clearly cascaded and communicated throughout the 
organization. Tools that could be used to address this included Brain Storming, Affinity 
Diagram and Stakeholder Mapping. It could also be used to help with setting the 
direction based on the business and healthcare environment as well as the organization's 
current business, strengths and competencies. 
2: Develop a map of the Pharma industry value stream across the product life 
cycle 
The value stream map is a good tool for helping to understand all the components 
in a business, process, system or any entity that have some form of life cycle. In this case, 
a value stream map can be developed based on the 4 problem areas identified directly by 
the research and restated by the interview participants. The lifecycle below (Table 10) 
goes from the identification of a therapeutic area to focus on to the delivery of the 
product and services required to meet the patient need.  
Table 10 - Example of One Representation of the Pharmaceutical Value Stream 
 
Components Associated with  this Proposed Product Lifecycle Value 
Stream 
 
Area of 
Focus  
Identify 
Therapeutic 
Opportunity 
R&D  FDA & 
Compliance 
Manufacturing  
& Production 
Marketing Sales Services 
Lack of NCE 
Approvals 
High High Medium Medium Medium Medium Medium 
Generic 
Competition 
Medium Low Low High High Medium Medium 
Regulatory 
Changes & 
Political Impact 
Medium Low High Low Medium Medium Low 
Emerging 
Markets  
High Medium Low High Low High Medium 
 
 
High = High correlation between the area of focus and the value stream components 
Medium = medium co-relation area of focus and the value stream components 
Low = Low co-relation between the area of focus and the value stream components 
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Note: The co-relations above are relative because it is recognized that as an industry all 
the factors are related in one or many different ways. 
 
The value stream map above would be a good tool for helping the organization to 
decide on where to focus their resources and energies, based on their strategies and 
competencies. For example, if the Emerging Markets is the area in which a company was 
placing its strategic bet, the table above suggests that Identifying Therapeutic 
Opportunity, Manufacturing and Production and Sales should be the highest priority 
followed by R&D and Marketing. This value stream in this case would help to decide on 
relative importance of each component to achieving their objective. 
 
3: Develop a preliminary business case for the decision that needs to be made 
regarding M&A and other partnerships and assess the cost of integration. 
After making the strategic decision to focus on a particular therapeutic area, it is 
very important that the company creates a business case using the best information 
available, taking into consideration all the costs and expenses that will be associated 
implementing the strategy. In these situations GAAP (General Accepted Accounting 
Principles) are a good baseline for companies to use. It is also important to have a good 
understanding of the financial stability or not of companies that will be engaged in the 
proposed M&A or partnership. This is especially important when the business agreement 
is being done with entities or organizations that may be in countries that have different 
accounting, financial, quality, safety, legal and contracting rules and standards. 
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4: Create a SIPOC for each area (e.g. R&D, Marketing etc) to see where there 
may be gaps or lack of alignment based on the organization's competence or 
capabilities: 
A SIPOC (Supplier Input Process Output Customer) diagram which is tool 
usually used as part of a Six Sigma process can be very useful in helping an organization 
dig deeper to better understand the details involved in a particular process or operation. 
As an example, this process could be used to address the R&D component that is a high 
priority in the area of Emerging Markets. This is a very good tool for getting to 
understand potential issues and hidden costs. 
If a company is looking to invest in R&D in the Emerging Market, it is very 
important that they develop an understanding of where and how the resources, (human, 
capital and natural) will be acquired and deployed. Knowledge of local transportation 
access, laws, customs and politics is also very important to attain to be able to properly 
assess the feasibility of setting up operations in the targeted country and is critical for 
understanding supply chain considerations (see Figure 10). 
Figure 10 - Example of a SIPOC (that could be created for the Manufacturing and 
Production Component to address Emerging Market Concerns) 
 
e.g. Products  
and services  
made available 
to doctors and 
patients at  
affordable costs 
e.g. Skilled  
workers, access  
to raw materials 
and  
manufacturing 
space 
 
e.g guidance  
from R&D,  
Compliance, 
Regulatory,  
 Legal, 
Marketing,  
Sales,  
Management  
 
e.g. Specific 
step by step 
directions,  
systems and  
manufacturing  
expertise 
e.g. Products  
and services  
to address the 
unmet needs 
Supplier Input Process Output Customer 
Feedback Loop 
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The same process could be used in every component associated with the value 
stream map of the life cycle because taking a 'system approach' to assessing the suppliers, 
inputs, processes, outputs and customers can help to eliminate unwanted surprises and 
hidden costs or problems. 
5: Make buy, build, acquire or partner decisions based on the need identified 
above as well as the organization's strategy and integration capabilities. 
Once the proper assessment has been done using the value stream map to 
understand the key areas and priorities, the business case to determine the feasibility of 
the endeavor and the SIPOC to understand what is required in more details, the 
organization needs to decide on the best way to more forward.  
Some of the decisions that have to be made in the Manufacturing and Production 
component to the value stream map to address the Emerging Market opportunities 
include;  
1. Should manufacturing space be rented or purchased?  
2. Should workers be recruited and trained locally or should they be brought in from 
other regions or countries? 
3. Should all the production be done in-house or should certain aspects be 
subcontracted to local companies? 
4. How will safety and compliance issues be addressed and should what impact will 
that have on downstream marketing and sales? 
These are just a representational set of questions that will need to be addressed. 
On one hand there has to be focus on creating the most efficient manufacturing 
and production process, but just as important is the need to recognize that from a political 
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and business standpoint, there may be a need to use local workers, contractors and respect 
customs that may not be the most efficient in order to be gain local acceptance and 
conduct business. The answers to these questions have to be answered and reflected in 
the business case and other assessments to ensure that these realities are reflected in the 
decisions being made. 
 
6: Update the business case and financials and create an implementation and 
integration office to execute the strategy 
With any business activity, doing the assessment and making the decision to 
implement the strategy are just the first steps. Strategies and solutions need to be well 
thought out and not done in isolation which could lead to implementing tactics which do 
not support or compliment each other or align with the strategy. In order to realize the 
targeted objectives, it will be necessary to setup the necessary organizational structures, 
programs and projects needed to meet the objectives. A system of checks and balances to 
monitor and control the process is also critical. Throughout the implementation process it 
will be necessary to maintain the financial rigor and due diligence needed to ensure that 
the decisions and investments made continue to make good business sense. 
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CHAPTER 10 
 
CONCLUDING THOUGHTS 
 
Observations 
The issues outlined in the Pharma industry and the potential long term impacts are 
very real. It is a combination of the economic issues being faced globally as well as the 
industries inability to produce new products and services that meet the evolving needs of 
patients, current and future. If there is any doubt that companies are aware of the 
problems and are trying to make strategic and tactical moves to change, one only has to 
take a sampling of the headlines in Pharma magazine publications to get some 
perspectives. Below are the headlines captured from FiercePharma.com in just one week, 
that highlights some of the issues companies are facing as well as the actions they are 
taking to position themselves for future growth: 
Astellas launches $3.5B bid for OSI (March 1, 2010) 
California county sues GSK over Avandia (March 1, 2010) 
AZ pitches social-media rules to FDA (March 2, 2010) 
UK calls summit over medicine shortages (March 2, 2010) 
Pfizer rejoins Patiopharm race with $4B bid (March 3, 2010) 
Teva regains exclusivity on Merck meds (March 3, 2010) 
FDA aims to step up criminal prosecutions (March 4, 2010) 
How will new BMS chief replace $11B? (March 4, 2010) 
Few pharmas to profit off CV growth (March 5, 2010) 
GSK faces up to $6B Avandia liability (March 5, 2010) 
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The headlines clearly show that companies are not sitting back and waiting for 
things to change. Most are actively looking for ways to gain valuable assets as well as 
look for ways to engage with the FDA and deal with competition from generic drug 
makers. Companies also have to deal with the legal actions that often follow any reports 
or accusation of product risk or safety issues, again a big drain on their resources as well 
as revenue.  
Research Summary 
There is no magic solution that can address all the issues outlined in this thesis. 
The Pharma industry and individual companies will have to look deeply within 
themselves and make a conscious decision to change. Every industry has certain 
characteristics which tend to be more or less representational of the companies in the 
industry. In general big Pharma companies have grown up over the years from the mid 
1970s to the early 2000s with the understanding that if they pour money into R&D and 
start with a large number of candidate molecules, at some point it will pay off with one or 
two major drugs from the batch.  
The current realities no longer support that philosophy. The lack of approval of 
new and innovative products with very high patient value makes it hard for companies to 
realize the growth they had in earlier years. The proliferation of generic drug makers 
along with a slew of patents expiring means that the revenue stream for branded products 
can go from hundreds of millions of dollars to tens of millions of dollars or less in a 
matter of 6 months. The scrutiny and pressure from regulatory agencies to abide by 
higher safety standards minimize risks and prove greater efficacy means that more time, 
effort and money have to be invested in upgrading processes and infrastructure. Added to 
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that is the every present legal and political risks that have to be managed and mitigated 
whenever there are accusations or reports of product issues. Slower growth in the 
developed countries necessities looking at the opportunity to develop business and 
operations in the Emerging Markets, but along with these opportunities there are also 
significant threats and this is still an area in which most big Pharma companies have 
limited expertise. 
Interview Recap 
One common view expressed in the interviews conducted with the Pharma 
professionals was that the current Pharma model from research and development through 
marketing and sales is broken. This was very much in line with the results of the research. 
The interviewees were encouraged that there was evidence that some companies were 
changing and trying to add more value and me effective in some areas, but in general 
they felt that there was no organized or concerted effort being made to bring about the 
major changes that will be needed to turn the industry around. They felt that there is room 
for collaboration that can reduce operating cost and other industry costs and still have a 
place for healthy competition based on introducing innovative medicines to help with 
patient care meet the needs of stakeholders and shareholders at the same time. The 
Partnership between Eli Lilly, Merck and Pfizer will hopefully be a model for how this 
will be able to work. 
 Considerations 
Chapters 5 through 9 outline some key steps that that companies can make in both 
the short and long term to make the changes necessary to be proactive and in some cases 
respond to the issues being faced in the industry. Not only is it important to identify the 
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right steps to do, it is also important to do these steps in the right way. In other words, in 
order to be successful, the first steps may be getting the required funding, skilled 
employees, processes, infrastructure and strategy from well meaning executives and 
senior managers. However, it is also very important to realize that making all these things 
work well together in order to achieve the desired results is not automatic.  
The dynamics involved in getting an organization to functions at its best to 
achieve the targeted objectives is very complex, and has to be understood and planned for 
at every level. This will require global and regional understanding of history, cultures, 
beliefs, values and societal norms. At the country level it will require knowledge of the 
culture, politics, business and constitutional law, infrastructure, supply chain and the 
people. At the organizational level a lot of work has to be done to assess and understand 
not only what motivates and inspires creativity and productivity of the current employees, 
but also any employees that may become a part of the organization as a result of a M&A 
or other forms of partnerships. It would take significant effort in the areas of Change 
Management, Integration Management, Process Management, Portfolio Management, 
Program Management and Project Management to be able to plan and execute any 
strategy that is developed. 
It would be possible to write a complete thesis on any one of the organizational 
topics listed above, referencing concepts like the theory of needs (Maslow), looking at 
what motivates individuals or how people behave as individuals versus in a group, 
organizational or country setting. It could also consider how people respond to threats 
and rewards, real or perceived. These thoughts are central to any work that would be 
needed to implement the changes needed for companies to make the shift from 'business 
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as usual' to a new way of thinking and functioning. The steps listed above assumes that 
the leaders of the companies not only have the skills, knowledge, experience, will and 
intelligence quotient (IQ) needed to make these changes, it also assumes that these 
leaders have the emotional intelligence quotient (EQ) needed to understand the 
psychological and sociological factors at play. 
Conclusion 
When looking at the industry from a global standpoint it is clear that there are 
opportunities to address un-met medical need in many therapeutic areas and regions of 
the world. It is also clear that with this very complex industry, making the changes 
necessary will not be easy, and it will not happen overnight. To be successful in the 
future Pharma companies will have to find ways to deliver the medicines and solutions 
needed to meet the diseases of today and the future. Companies need to find a way to 
make science and technology work with business needs in an efficient way to benefit all 
stakeholders. As companies embark on this journey, they need to devote as much time 
and effort to clearly communicate their strategies to employees, customers and other 
stakeholders, planning for change and structuring their organizations for success.  
Many companies are well on the way to changing their organizational strategies 
as well as their operations to meet the challenges they face. Mergers and acquisitions and 
other forms of partnerships have been a big part of these changes, and their long term 
strategic impact and performance is still being played out so it is too early to draw 
conclusions. It is important for individual companies and the Pharma industry to listen to 
their stakeholders and spend time assessing their options, strategies and most importantly, 
understanding the long term needs of patients before they invest heavily in any particular 
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area. This will go a long way towards demonstrating that they are serious about meeting 
patient needs, and the stakeholders at every level will benefit as a result of these actions. 
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GLOSSARY 
Affinity Diagram – Tool that gathers large amounts of language date (opinions, ideas, 
issues) and place them into groupings or categories based on their natural relationships 
Big Pharma – Top 10 global Pharmaceutical companies based on 2008 sales. Big 
Pharma is also used to describe companies with revenues in excess of $3 billion per year 
Blockbuster Drug – a drug that achieves annual revenues of over US 1 billion dollars at 
a global level (Ref - Pharmaceutical Sector Inquiry, Preliminary Report (DG 
Competition Staff Working Paper), 28 November 2008, page 17 (pdf, 1.95 MB 
Commonwealth of Independent States – A regional organization whose participating 
countries are former Soviet Republics formed during the breakup of the Soviet Union. 
EBIT (Earnings Before Interest Tax) – Financial measure of a company's earning 
power from ongoing operations before interest payments and income taxes are deducted. 
It normally does not include income and expenses from unusual, non-recurring or 
discontinued activities. 
Emotional Intelligence Quotient (EQ) – The ability, capacity, skill to perceive, assess 
and manage the emotions of one's self, others and groups 
Generally Accepted Accounting Principles (GAAP) – The Americanized term used to 
refer to the standard framework of guidelines for financial accounting used in any given 
jurisdiction which are generally known as accounting standards 
IMS Health – Company that provides pharmaceutical intelligence, information and 
consulting services to the healthcare market 
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Lymphatic Filariasis -  a disfiguring disease prevalent in tropical and sub-tropical 
countries. Transmitted by mosquitoes, it can lead to severe swelling of the arms, legs, 
breasts and genitals and thickening of the skin. 
Patent Cliff – Term to describe the loss of revenue of $140 billion in annual sales by 
2016 as key product patents expire and the generic version enter the market. This is 
expected to get to its peak in 2011/2012 when name brand drugs like Pfizer's Lipitor, 
GlaxoSmithKline's Advair, Sanofi-Aventis and Bristol-Myer's Plavix and AstraZeneca's 
Seroquel 
Mid sized pharma – Pharmaceutical companies positioned 11 – 50 based on 2008 sales 
River Blindness - River blindness is a debilitating disease that threatens the health and 
livelihood of more than 100 million people in parts of Africa, Latin America and the 
Middle East. Transmitted through the bite of black flies, river blindness causes intense 
itching and painful skin lesions, and it can eventually lead to the permanent loss of sight 
Small pharma – Pharmaceutical companies positioned 51 – 150 based on 2008 sales 
SIPOC diagram - a tool used by a team to identify all relevant elements of a process 
improvement project before work begins. It helps define a complex project that may not 
be well scoped 
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APPENDIX A 
CAPSTONE INTERVIEWEES 
 
Name Title Brief Summary of Experience 
Mr. Blair 
Gibson 
Executive Director of 
Portfolio Strategy & 
Planning (Merck & 
Co.) 
23 years in the Pharma industry with global 
experience in Portfolio Strategy and Planning, 
Product Launches and New Products 
Management 
Dr. David 
Reibstein 
Author, Consultant  
& Professor of 
Marketing (The 
Wharton School, 
University of 
Pennsylvania) 
30 years experience as a professor of Marketing 
with major awards and publications. Extensive 
Global Consulting with major corporations 
Garry Neil 
M.D. 
Corporate VP, 
Corporate Office of 
Science and 
Technology (J&J 
Services Inc) 
Broad experience in science, medicine and 
pharmaceutical development (18 years 
Pharma). Senior positions within J&J, most 
recently Group President, Johnson and Johnson 
Pharmaceutical Research and Development 
Ms. Janet 
Keyser 
Executive Director, 
Development 
Integration (Merck & 
Co.) 
Responsible for integration of Transformational 
Change in Research Laboratories Division of 
Merck & Co.,  Various leadership positions in 
Clinical Quality Assuarance and Global Process 
Development (29 years experience) 
Mr. Marvin 
Johnson 
National Sales 
Director, 
Neuropsychiatry 
(Merck & Co.) 
25 years experience in the Pharma industry in 
Marketing and Sales including Global 
Franchise Brand Leadership. 
Mr. Michael 
Lombardo 
Executive Director, 
Marketing Process 
Management (Merck 
& Co.) 
19 years experience in the Pharma industry in 
Marketing and Sales including Global 
Franchise Brand Leadership and Process 
Management 
 
 
 
 
 
 
 
58 
APPENDIX B 
 
CAPSTONE QUESTIONAIRE 
 
1: In your opinion, how has 'Big Pharma' changed over the past 10 years? 
 
2: What are the 5 top critical factors that have led to these changes and how would you 
rank them in terms of the impact they have caused? Rank each on a scale of 1 – 5 (with 1 
being the highest impact and 5 being the lowest impact) 
 
3: What are the top 3 to 5 commercial issues that companies need to resolve to ensure 
future success, and why?  Please be specific and categorize the issues as short-term (1 to 
3 years) or long-term (3 to 5 years).  
 
4: What are the top 3 to 5 scientific (research and development driven) issues that 
companies need to resolve to ensure future success, and why?  Please be specific and 
categorize the issues as short-term (1 to 3 years) or long-term (3 to 5 years).  
 
5: How would you describe the 'Big Pharma's' strategic plan to increase innovation and 
productivity? 
 
6: Why have most previous mega mergers failed to deliver long term benefits to buyers 
and shareholders and how do you think companies such as Pfizer and Merck will avoid 
repeating industry's past mistakes 
 
7: Many companies are making strategic decisions to change their business models (R&D 
and commercial) by taking a variety of approaches for example, diversification, 
partnerships, mergers and acquisitions to name a few. What are the top 3 to 5 things that 
companies need to do now to ensure that the successful implementation of these 
strategies? 
8:  What approaches are 'Big Pharma' companies taking to manage merged/acquired 
portfolio of assets? 
9: In once sentence, please explain the importance of the following for ensuring top line 
growth for 'Big Pharma?' 
 
 R&D  
 Marketing and Sales 
 The Emerging Market/Globalization 
 Demographics 
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